AstraZeneca, one of the world's leading pharmaceutical companies, has reinforced its commitment to the Chinese mainland by investing $700 million in a new inhaled medicines manufacturing site located in Qingdao City, Shandong Province. This substantial investment underscores the British biopharmaceutical giant's belief in the Chinese mainland as a prime hub for innovation.
Leon Wang, AstraZeneca's Executive Vice President, emphasized the strategic importance of this move in an interview with CGTN host Lincoln Humphries. \"The Chinese mainland is the best location for innovation,\" Wang stated, highlighting the region's growing capabilities in pharmaceutical research and development.
This expansion not only boosts AstraZeneca's production capacity but also aims to enhance the accessibility of advanced inhaled therapies to a broader population. By leveraging local expertise and resources, AstraZeneca is poised to drive forward breakthroughs in respiratory medicine, catering to both domestic and global markets.
Reference(s):
cgtn.com
